X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA IPCA LABS PLETHICO PHARMA/
IPCA LABS
 
P/E (TTM) x -1.1 35.0 - View Chart
P/BV x 0.0 3.3 0.5% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 PLETHICO PHARMA   IPCA LABS
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
IPCA LABS
Mar-17
PLETHICO PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs395643 61.4%   
Low Rs31503 6.2%   
Sales per share (Unadj.) Rs604.4254.4 237.6%  
Earnings per share (Unadj.) Rs32.516.1 202.1%  
Cash flow per share (Unadj.) Rs51.329.8 172.4%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs473.6194.6 243.4%  
Shares outstanding (eoy) m34.08126.20 27.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.42.3 15.7%   
Avg P/E ratio x6.635.7 18.4%  
P/CF ratio (eoy) x4.219.2 21.6%  
Price / Book Value ratio x0.52.9 15.3%  
Dividend payout %06.2 0.0%   
Avg Mkt Cap Rs m7,26272,300 10.0%   
No. of employees `000NA13.3 0.0%   
Total wages/salary Rs m1,5966,960 22.9%   
Avg. sales/employee Rs ThNM2,413.5-  
Avg. wages/employee Rs ThNM523.2-  
Avg. net profit/employee Rs ThNM152.4-  
INCOME DATA
Net Sales Rs m20,59832,106 64.2%  
Other income Rs m386226 171.2%   
Total revenues Rs m20,98432,332 64.9%   
Gross profit Rs m2,8184,448 63.3%  
Depreciation Rs m6421,730 37.1%   
Interest Rs m1,593241 661.6%   
Profit before tax Rs m9692,703 35.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-138675 -20.5%   
Profit after tax Rs m1,1072,028 54.6%  
Gross profit margin %13.713.9 98.7%  
Effective tax rate %-14.325.0 -57.2%   
Net profit margin %5.46.3 85.1%  
BALANCE SHEET DATA
Current assets Rs m18,87717,340 108.9%   
Current liabilities Rs m11,8969,559 124.4%   
Net working cap to sales %33.924.2 139.8%  
Current ratio x1.61.8 87.5%  
Inventory Days Days36100 35.8%  
Debtors Days Days19857 347.9%  
Net fixed assets Rs m9,86120,779 47.5%   
Share capital Rs m341252 135.0%   
"Free" reserves Rs m12,33124,499 50.3%   
Net worth Rs m16,13924,553 65.7%   
Long term debt Rs m4,7063,517 133.8%   
Total assets Rs m33,14639,595 83.7%  
Interest coverage x1.612.2 13.2%   
Debt to equity ratio x0.30.1 203.5%  
Sales to assets ratio x0.60.8 76.6%   
Return on assets %8.15.7 142.2%  
Return on equity %6.98.3 83.0%  
Return on capital %12.310.5 117.2%  
Exports to sales %21.448.6 43.9%   
Imports to sales %15.214.2 106.9%   
Exports (fob) Rs m4,40215,617 28.2%   
Imports (cif) Rs m3,1364,571 68.6%   
Fx inflow Rs m4,40215,617 28.2%   
Fx outflow Rs m3,1845,828 54.6%   
Net fx Rs m1,2199,790 12.4%   
CASH FLOW
From Operations Rs m2,4372,764 88.2%  
From Investments Rs m-6,265-1,432 437.6%  
From Financial Activity Rs m2,490-1,591 -156.5%  
Net Cashflow Rs m-1,337-259 516.7%  

Share Holding

Indian Promoters % 82.7 45.9 180.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 11.4 37.7%  
FIIs % 5.5 25.3 21.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 17.4 43.1%  
Shareholders   10,665 36,892 28.9%  
Pledged promoter(s) holding % 85.7 2.1 4,006.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   SUVEN LIFE  SHASUN PHARMA  MERCK LTD  DIVIS LABORATORIES  TTK HEALTHCARE  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 219 Points Lower; Energy and Auto Stocks Witness Selling(Closing)

After witnessing volatile trades during the day, Indian share markets ended their session on a negative note. Losses were largely seen in the oil & gas sector, auto sector.

Related Views on News

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS